Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

RCT | Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis.

20 Sep, 2022 | 13:20h | UTC

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet

Commentary: Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years – HealthDay

 

Guideline Summary | Management of patients with suspected or confirmed antibiotic allergy.

8 Sep, 2022 | 14:42h | UTC

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

Related:

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 

European guideline (EuroGuiDerm) on atopic eczema – Part II | Non-systemic treatments and treatment recommendations for special AE patient populations.

5 Sep, 2022 | 14:32h | UTC

European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations – Journal of the European Academy of Dermatology and Venereology

Related: European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy – Journal of the European Academy of Dermatology and Venereology

 

Guideline | Management of kidney transplant patients with HLA antibodies.

31 Aug, 2022 | 11:47h | UTC

European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group – Transplant International

 

Clinical practice guidelines for the management of atopic dermatitis.

24 Aug, 2022 | 14:13h | UTC

English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021 – The Journal of Dermatology

 

European guideline on atopic eczema – Part I: systemic therapy.

19 Aug, 2022 | 16:14h | UTC

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy – Journal of the European Academy of Dermatology and Venereology

 

Review | Plasma exchange in the intensive care unit.

15 Aug, 2022 | 12:19h | UTC

Plasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine

 

Commentary on Twitter

 

M-A | Interventions to reduce infections in patients with hematological malignancies.

15 Aug, 2022 | 11:51h | UTC

Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis – Blood Advances

Commentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC

 

Consensus Statement | Pharmacological management of allergic rhinitis.

11 Aug, 2022 | 12:10h | UTC

Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology – Journal of Asthma and Allergy

Related:

Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters – Annals of Internal Medicine

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis – Allergy Asthma & Immunology Research

 

Guideline | Management of immunoglobulin replacement therapy.

5 Aug, 2022 | 14:35h | UTC

British Society for Immunology & United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy – Clinical and Experimental Immunology

 

M-A | Treating eosinophilic esophagitis with budesonide.

27 Jul, 2022 | 12:06h | UTC

A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide – Annals of Medicine

 

RCT | Efficacy and safety of Abrocitinib vs. Dupilumab in adults with moderate-to-severe atopic dermatitis.

25 Jul, 2022 | 12:44h | UTC

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial – The Lancet (link to abstract – $ for full-text)

Related: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis – New England Journal of Medicine

 

Systematic Review | Anti‐IL‐5 therapies for asthma.

14 Jul, 2022 | 12:40h | UTC

Anti‐IL‐5 therapies for asthma – Cochrane Library

Summary: Mepolizumab, reslizumab or benralizumab for people already taking inhaled steroids and long-acting beta 2-agonists for their asthma – Cochrane Library

 

M-A | Prenatal antibiotic exposure, asthma, and the atopic march.

8 Jul, 2022 | 11:31h | UTC

Prenatal antibiotic exposure, asthma, and the atopic march: A systematic review and meta-analysis – Allergy

 

Review | Cough hypersensitivity and chronic cough.

4 Jul, 2022 | 12:59h | UTC

Cough hypersensitivity and chronic cough – Nature Reviews Disease Primers (if the link is paywalled, try this one)

See also: Infographic (if the link is paywalled, try this one)

 

Commentary on Twitter

Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug.

4 Jul, 2022 | 12:57h | UTC

Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug – Science

See also: SARS-CoV-2 can evade Paxlovid by multiple mechanisms – News Medical

Opinion | FDA: Don’t rush a move to change the Covid-19 vaccine composition.

4 Jul, 2022 | 12:53h | UTC

FDA: Don’t rush a move to change the Covid-19 vaccine composition – STAT

Antibodies to combat viral infections: development strategies and progress.

4 Jul, 2022 | 12:51h | UTC

Antibodies to combat viral infections: development strategies and progress – Nature Reviews Drug Discovery (if the link is paywalled, try this one in PMC)

Consensus for the definition, classification, diagnosis, and management of urticaria.

1 Jul, 2022 | 11:32h | UTC

Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria: A 2021 update – Journal of the Formosan Medical Association

 

Survey: The multidimensional burden of atopic dermatitis among adults.

30 Jun, 2022 | 10:57h | UTC

The Multidimensional Burden of Atopic Dermatitis Among Adults: Results From a Large National Survey – JAMA Dermatology

 

RCT: A 2-week interruption in methotrexate treatment doubles the antibody response to a COVID-19 booster vaccine.

29 Jun, 2022 | 12:10h | UTC

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial – The Lancet Respiratory Medicine

News Releases:

Interrupting the treatment of vulnerable people on immune-suppressing medicines, doubles their antibody response to COVID-19 booster vaccination – University of Nottingham

Interrupting immune-suppressing treatment can boost COVID vaccine response – Imperial College London

Commentaries:

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment – The Lancet Respiratory Medicine

Covid-19: Pausing immune suppressing drugs enhances antibody response to boosters, study shows – The BMJ

Related Study: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial – Annals of Rheumatic Diseases

 

Commentary on Twitter

 

Guideline for the emergency management of anaphylaxis.

28 Jun, 2022 | 10:59h | UTC

A Clinical Practice Guideline for the Emergency Management of Anaphylaxis – Frontiers in Pharmacology

Related:

Wilderness Medical Society Clinical Practice Guidelines on Anaphylaxis – Wilderness and Environmental Medicine

Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update – Allergo Journal International

EAACI guidelines: Anaphylaxis (2021 update) – European Journal of Allergy and Immunology

 

Review: Management of moderate-severe atopic dermatitis in pediatric age.

27 Jun, 2022 | 11:32h | UTC

Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP) – Italian Journal of Pediatrics

 

Analysis of 7 RCTs: Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis.

27 Jun, 2022 | 10:56h | UTC

Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis – The Journal of Allergy and Clinical Immunology: In Practice

Commentary: Treatment Reduces, Exterminates Hospitalizations in Adults With Moderate to Severe AD – Consultant360

 

Commentary on Twitter

 

EULAR/ACR points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases.

24 Jun, 2022 | 11:23h | UTC

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist – Annals of Rheumatic Diseases

 

Stay Updated in Your Specialty

No spam, just news.